4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 500.00
-40.00 (-7.41%)
Mar 5, 2026, 8:03 AM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 83.58 million as of March 4, 2026. Its market cap has decreased by -41.72% in one year.
Market Cap
83.58M
Enterprise Value
72.90M
Revenue
1.78M
Ranking
n/a
PE Ratio
n/a
Stock Price
500.00
Market Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 83.58M, an increase of 101.05%. That is a compound annual growth rate of 14.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 3, 2026 | 83.58M | -12.20% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Avacta Group | 299.62M |
| Scancell Holdings | 129.98M |
| Bioventix | 78.37M |
| Faron Pharmaceuticals Oy | 67.15M |
| Hemogenyx Pharmaceuticals | 60.33M |
| hVIVO | 55.11M |
| Ondine Biomedical | 53.25M |
| ImmuPharma | 34.94M |